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F. Sattarov
Praemonitus, praemunitus: Assessing
the ethical dimension of the globalisation
of science and technology*
Sattarov F.F., PhD Assistant Professor, Department of Social and Political Sciences, University
of World Economy and Diplomacy.
Introduction
Globalisation can be understood as “the intensification of worldwide
social relations which link distant localities in such a way that local
happenings are shaped by events occurring many miles away” [1]. Globali-
sation is undoubtedly a prominent feature  of contemporary life. Together
with social, economic, and cultural processes of globalisation, there  has
also been an intensification of the globalisation of science and technology
[2]. In recent years, there has been a growing awareness of ethical issues
resulting from the globalisation of science and technology. For example,
the globalisation of science and technology can result in “ethics dump-
ing”. “Ethics dumping” describes a situation in which a multinational
company or corporation deliberately moves its laboratory experiments to
a country that does not have ethical or legal
standards for governing such laboratory exper-
iments. In this way, the multinational compa-
ny can get away with dubious and questionable
practices, simply by moving them from one
country to another country.
* The present article draws on my research paper presented at an international conference on “Policy and Legal Options for
Developing Ethics Assessment for Research and Innovation within the Context of Globalisation”, held by UNESCO in Paris,
France, on 24-26 June, 2015.
In recent years, there has
been a growing awareness
of ethical issues resulting
from the globalisation of
science and technology.
ISSUES OF THEORY, METHODOLOGY AND PRACTICE
OF INTERNATIONAL STUDIES
 Õàë³àðî òàä³è³îòëàðíèíã íàçàðèé, óñëóáèé âà àìàëèé ìàñàëàëàðè 
 Âîïðîñû òåîðèè, ìåòîäîëîãèè è ïðàêòèêè
ìåæäóíàðîäíûõ èññëåäîâàíèé 
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The present article identifies and reviews the most important of such
ethical issues in a systematic fashion. But why catalogue ethical issues
resulting from the globalisation of science and technology? The answer
partly rests in the  fact that Uzbekistan is currently undertaking major
steps to liberalise the economy, to improve the investment climate and
to open up domestic markets to foreign businesses and investors. In
particular, the process of attracting foreign direct investment (FDI) in
the country will inevitably result in the establishment of various joint
ventures, acquisitions and greenfield enterprises [3], which in turn will
lead to the intensification of research and development activities with
foreign partners. However, as this paper aims to show, an increase in
science research and technology development with foreign partners can
have its own ethical and moral perils. Hence, to prepare the country and
society to avoid the negative effects and consequences of the scientific
and technological globalisation, it is necessary first to  have  a clear picture
of all possible ethical issues, particularly those which either remain
unaddressed by the domestic legal framework or stand outside the domestic
legislative agenda. In this way, a catalogue of ethical issues arising from
the globalisation of science and technology offered in the present study
provides policy makers, regulatory bodies, academic institutions, industry
and business representatives in this country with an informative list of
some of the major negative effects and implications of the globalisation
of science and technology. Proverbially speaking, forewarned means
forearmed.
In this article, research and innovation is broadly understood to consist
of three different stages: (1) research and development (R&D), (2)
manufacture  and production, and (3) marketing and sales. During the
first stage, a new product or a process is designed and developed; during
the  second stage, mass manufacture  and production of the  innovation in
question takes place; during the  third stage, the  innovation in question is
diffused within society. Research and innovation
can be said to be globalised insofar as any of the
above  three  stages occurs on an international or
global level, thus involving globally distributed
R&D, production and sales networks. The present
review focuses on ethical issues that stem from
the globalisation of any of the above three stages.
At the R&D stage of innovation, there exist a number of important
ethical problems, such as issues pertaining to the maintenance of ethical
standards in the  outsourcing of R&D to  developing countries; issues of
informed consent and benefit-sharing in the development and patenting of
An increase in science
research and technology
development with foreign
partners can have its own
ethical and moral perils.
F. Sattarov
2
International Relations: Politics, Economics, Law, Vol. 2019 [2019], Iss. 2, Art. 11
https://uzjournals.edu.uz/intrel/vol2019/iss2/11
63Xalqaro munosabatlar, 2019, ¹ 2.
innovations on the basis of local knowledge
and biological resources; issues of (global)
resource  allocation and distributive  justice
in funding clinical and medical R&D; issues
pertaining to the impact of globalisation of
research and innovation on scientific integrity
and responsible conduct of research; as well
as the issue of ‘brain-drain’ from developing
countries as a result of the globalisation of
R&D. Ethical issues that arise  during the  production and manufacture
stage of innovation include issues concerning the adoption and maintenance
of ethical standards in outsourcing production processes, with regard to
the  local workers or community (e.g., outsourcing of production to  countries
with lower wages or lower standards for health and safety and protection
of human rights), the  local environment (e.g., outsourcing of production
processes, CO2 emissions and waste disposal to countries with lower
environmental standards); as well as the question and extent of adherence
of supply chains to ethical standards. Finally, at the marketing and sales
stage there are ethical issues pertaining to accessibility or affordability of
products and processes in different countries, as well as responsibility and
liability for health, environmental and other harms that might result from
the marketed and sold products.
Ethical issues at the R&D stage
1. Outsourcing of R&D to developing countries
One of the aspects of the globalisation of research and innovation is
the  outsourcing (or offshoring) of R&D to  developing countries such as
India, Brazil and South Africa. Among chief reasons for such outsourcing,
one  can include  the  availability of cheaper labour and talent, cheaper
infrastructure, lower health and environmental safety standards, etc.
Important ethical issues become increasingly prominent in the area of
outsourcing of pharmaceutical and clinical research and trials to  such
developing countries. Pharmaceutical research and trials usually consist of
three different stages. The first is to test the toxicity and pharmacokinetics
of the pharmaceutical innovation in question, which normally involves
tests conducted on a smaller group of healthy people. The second is to
evaluate the efficacy of the pharmaceutical, that is, whether or not it
works as intended. The third is to compare the safety and efficacy of the
pharmaceutical in question with those other existing alternatives. (Recently
there  has been a new addition – a fourth stage  of pharmaceutical trials –
that observes and records the long-term effects of the pharmaceutical
Among chief reasons for
outsourcing research and
development, one can include
the availability of cheaper
labour and talent, cheaper
infrastructure, lower health
and environmental safety
standards, etc.
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innovation, which can be conducted after the pharmaceutical is licensed.)
The later stages of clinical trials require and involve larger population
groups. The most important ethical issues are thus related to the use of
people from developing countries for clinical trials that involve larger
groups of people.
The  European Group on Ethics in Science  and New Technologies,
while commenting on “the ethical aspects of clinical research in developing
countries”, has noted that there has been “a trend to transfer clinical
trials to countries where cost and constraints of regulation may be more
favourable to their implementation, and where the high number of patients,
and especially naïve patients, that is patients who have never received
treatment, facilitates the recruitment of patients to be involved in a clinical
trial” [4]. Thus, the  central ethical concern is that in pursuit of profits
companies from developed countries conduct clinical research and trials in
the developing countries with less concern for health and safety and with
less financial expenditure  than in their own countries. Besides lax
regulatory environment, outsourcing of
pharmaceutical research to developing
countries can also be motivated by political
corruption, postcolonial attitudes, high level
of illiteracy and particular perception of
medical research among local population, etc.
Furthermore, it is not only clinical trials
involving humans, but also trials involving
animal testing (e.g., for purposes of testing
pharmaceuticals, cosmetics, etc.) that are
being outsourced to  developing countries.
Under such circumstances, pharmaceutical firms and laboratories can
resort to what has been described as “double standards” and/or “ethics
dumping”, which refer to a situation in which research that is considered
unethical in certain (developed) countries is conducted in (developing)
countries with less stringent, or altogether non-existent, ethical regulations
and standards [5]. Insofar as the human clinical trials are concerned, it is
possible  to  identify the  four most common concerns that frequently crop
up in discussions of ethics dumping and double standards: (1) whether
proper informed consent can be  obtained from the  research participants;
(2) whether payment and other benefits offered to  research participant
constitute undue inducement; (3) whether there is a fair proportion of
risk to  benefit for research participants; (4) whether research participants
are provided with the best standard of care. These and other issues are
considered in more detail below.
the central ethical concern is
that in pursuit of profits
companies from developed
countries conduct clinical
research and trials in the
developing countries with less
concern for health and safety
and with less financial
expenditure than in their own
countries.
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2. Issues in and of obtaining informed consent
The  most central ethical criterion in protecting research participants
is informed consent – whether the research is conducted in the developed
or the  developing world. For the  purpose  of protecting the  individual
research participants, it is necessary to  obtain their informed consent,
before the research can go ahead. The emphasis on the necessity for
informed consent has been established in the  Nuremberg Code  of 1947,
which first articulated the  codes governing scientific research to  ensure
the protection of individuals against the horrors perpetrated by the
Nazis in the name of scientific progress and the greater common good.
By adopting informed consent as a necessary criterion for assessing good
ethical research, the intention was to make it impossible for harmful
research and trials to be conducted. The importance of informed consent
has further been reiterated in the  Declaration of Helsinki of the  World
Medical Association (written in 1964, and amended nine times between
1975 and 2013).
Obtaining informed consent from potential research participants in
the developing world becomes problematic given the high levels of illiteracy,
especially within the  rural areas. Thus, the  level of literacy of a potential
clinical trial subject can sometimes be used as one of the proxy
measurements of the  subject’s ability to give  informed consent. Nonetheless,
possession of basic literacy cannot guarantee that a patient can fully
comprehend the  consequences of partici pating in clinical trials. For
example, in Germany, literate parents of children asked to take part in a
trial of a drug for hyperactivity and attention deficit disorder and
hyperactivity had difficulties understanding the  nature  of the  placebo
comparative group of the trial in question and did not fully grasp that the
main goal of the trial was research and not the provision of individualized
medical care [6]. It is well-documented that there is “the tendency among
patients to have an optimistic bias and
therapeutic misconceptions about trials”,
regardless of where the trial is conducted
[7]. It can be suggested that a way of
protecting potential research subjects from
taking part in clinical trials that might be
harmful to them is through the involvement
of family members in the decision-making
process. This, however, can raise  further
issues and questions regarding the
autonomy of individual patients.
The emphasis on the necessity
for informed consent has been
established in the Nuremberg
Code of 1947, which first
articulated the codes governing
scientific research to ensure the
protection of individuals against
the horrors perpetrated by the
Nazis in the name of scientific
progress and the greater
common good.
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3. Undue inducement
For clinical and pharmaceutical research to be considered ethical,
besides obtaining the  informed consent of potential participants, it is
important to consider whether the financial compensation, as well as the
other potential benefits offered for participation can come  to  constitute
undue  inducement [8]. Although research participants, particularly within
the  later stages of pharmaceutical trials are  usually reimbursed for
transportation, meals, etc., that is, expenses related to  participation in
the trial, even small amounts of monetary compensations such as these
might exert undue  influences on potential research participants in poor
and underdeveloped countries. However, to prohibit clinical trials in such
particularly poor places on the grounds that there is undue inducement
is involved might itself be an unethical approach, since such a decision
could be argued to be “paternalistic or even an instance of colonialism:
refusing the ‘poor’ options and choices on the grounds that the poor are not
capable of making these decisions for themselves” [9]. Moreover, if
participation in a research or trial is the
only way for a patient to access any kind
of health or treatment, then would it be
more ethical for the patient to have access
to it in this manner, than not to have any
medical check or treatment at all. This
argument echoes some of the views
expressed by participants of HIV research
and trials as documented in the Nuffield
report on the ethics of research related to
healthcare in developing countries [10].
4. A fair proportion of risk to benefit
Another of the issues encountered in assessing ethically good research
in developing countries has to do with the difficulty of ascertaining a fair
proportion of risk to  benefit for clinical trial participants. According to
this condition, benefits of the  trials for the  partici pant must be
proportionate  to  the  risk involved in participating in the  trial. The
emphasis on a fair proportion of risk to benefit primarily stems from
ethical concerns to protect the patient. However, with the globalisation
of research and innovation, a difficulty may arise in determining what can
be a fair proportion of risks to benefits, given that what counts as a fair
distribution of risks and benefits in one locality might be unfair in other
localities of the globe. Such a disparity in judgment has largely to do with
the fact that considerations of what is a fair proportion of risk to benefit
For clinical and pharmaceutical
research to be considered
ethical, besides obtaining the
informed consent of potential
participants, it is important to
consider whether the financial
compensation, as well as the
other potential benefits offered
for participation can come to
constitute undue inducement.
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is usually made by research ethics committees,
while there is no global homogeneity governing
and regulating how such committees should be
formed and how they should function.
Nevertheless, as Heather Widdows notes, “there
is significant overlap in the way they function
in practice and, as international pharmaceutical
companies and research networks function across
jurisdictions, harmonization is increasingly
taking place. What is important is that all international research goes
through a series of ethics reviews and core ethical issues are at least
considered” [11].
5. Standard of care: best global or best local?
Ascertaining a fair proportion of risk to  benefit furthermore  requires
that in developing a new drug a pharmaceutical company or laboratory
must know how effective their new innovation is in relation to already
existing drugs and treatments. Thus, for example, according to the
Declaration of Helsinki:
The  benefits, risks, burdens and effectiveness of a new intervention
must be  tested against those  of the  best current proven intervention,
except in the following circumstances:
- The use of placebo, or no treatment, is acceptable in studies where
no  current proven intervention exists; or
- Where for compelling and scientifically sound methodological reasons
the use of placebo is necessary to determine the efficacy or safety of an
intervention and the patients who receive placebo or no treatment will
not be subject to any risk of serious or irreversible harm. Extreme care
must be taken to avoid abuse of this option. [12].
However, the question of what constitutes “the best current proven
intervention” can become  a source  of controversy under conditions of the
globalisation of research and innovation.
Consider, for example, the Zidovudine case,
which involved a clinical trial conducted by
GlaxoSmithKline in 1985 (then called
Burroughs Wellcome) aiming to  assess the
effectiveness of an anti-retroviral drug, called
Zidovudine, to lessen the chances of
transmissions of HIV from the mother to a
baby during pregnancy or childbirth. Being a
placebo-controlled trial, it consisted of two
Another of the issues
encountered in assessing
ethically good research in
developing countries has to
do with the difficulty of
ascertaining a fair proportion
of risk to benefit for clinical
trial participants.
Ascertaining a fair proportion
of risk to benefit furthermore
requires that in developing a
new drug a pharmaceutical
company or laboratory must
know how effective their new
innovation is in relation to
already existing drugs and
treatments.
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groups of trial participants. While  one  group
was given Zidovudine, the other was given a
placebo [13]. As can be seen, this trial did not
answer the requirements of the Declaration of
Helsinki, according to which any new drug must
be evaluated against “the best current prophylactic
diagnostic and therapeutic methods”. Thus, by
giving a placebo, the  trial participants in the
placebo group were put at risk of serious and
irreversible harm. When questioned about their actions, the conductors
of the trial defended themselves by claiming that since there was no
locally available medicine anyway, their decision to give the group a
placebo was ethically justified. Put differently, their claim was that the
participants in the  placebo  group were  not harmed, since  they would not
have been able to get globally available alternatives in their locality.
Thus, in the Zidovudine case, the conductors of the trial construed ‘the
best available’ as the actually available (or affordable) locally rather than
best available globally.
6. Bio-prospecting and bio-piracy
Besides outsourcing of clinical trials to  developing countries, the
globalisation of R&D can also take the form of bio-prospecting, which
can be understood as the systematic process of discovery and
commercialization of new bio-chemical compounds [14]. While bio-
prospecting can also consult indigenous knowledge about local biological
resources in search of new bio-chemical compounds, bio-prospecting can
become bio-piracy, once it involves an exploitative appropriation of
indigenous knowledge  or biological resources [15]. Thus, in such situation,
in order to  ensure  that bio-prospecting does not become  bio-piracy, it is
important that any appropriation of knowledge  or biological resources
from an indigenous community is not exploitative but beneficial to the
group in question. A review of literature  on research ethics and global
bioethics can show that at least two different models have been proposed
to deal with communal ethical issues pertaining to groups: (1) group
consent and (2) benefit-sharing. Below the  two approaches receive  further
elaborations.
7. Issues of obtaining group consent
When bio-prospecting research involves indigenous groups or
communities, it is sometimes required that the researchers should first
gain some form of group consent from the indigenous group or community.
The globalisation of R&D
can also take the form of
bio-prospecting, which
can be understood as the
systematic process of
discovery and commer-
cialization of new bio-
chemical compounds,
F. Sattarov
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However, this approach towards communal ethical issues has its own
shortcomings. Firstly, it can be argued that just like in the case of
individual informed consent, if something is chosen, it might not necessarily
be ethical [16]. Secondly, it can be argued that group consent approach
does not properly address more fundamental issues coercion, exploitation
and power structure  [17].
8. Is benefit-sharing possible?
A better solution to communal ethical issues is the benefit-sharing
approach According to this approach, it is necessary to share the benefits
gained from bio-prospecting research with those groups and communities
that provided forms of knowledge  or samples of biological resources.
According to the Human Gene Organisation (HUGO), indigenous groups
can be offered benefits such as health care, public-health-services
technology transfer and contribution to  the  local community infrastructure
(e.g., schools, libraries, sports, clean water).
There have been cases in which the benefit-sharing approach has worked
very well. Thus, for example, when a group of scientists have been studying
plants in the  Kani community in the  Thiruvananthapuram forest in India
in 1987, they discovered that people from
the local community could resist fatigue
far more effectively by eating a certain plant
called “arogyapacha”. Once the scientists
developed a synthetic and commercial
energy-enhancing product on the basis of
this plant, they allocated a part of their
profits to the local community and
implemented enhanced cultivation of the
plant for the indigenous community in
question [18].
9. Fair global resource allocation
The globalisation of R&D, in particular in the area of medicine and
pharmaceuticals, might also give rise to global ethical issues pertaining
resource  allocation and distributive  justice. Thus, for example, one  might
question, from the viewpoint of normative political ideal of (global)
justice, whether it is justifiable to develop expensive and technologically
sophisticated medical treatments, while most people in the world lack
access to basic health care. Those who adopt a strong cosmopolitan approach
would consider the disparity between different territories and regions of
the world as unjustified, by arguing that no ethical grounds could be
A better solution to communal
ethical issues is a benefit-
sharing approach, according to
which, it is necessary to share
the benefits gained from bio-
prospecting research with those
groups and communities that
provided forms of knowledge or
samples of biological resources.
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used to justify giving expensive treatments to some while others lack
basic health care. Yet, those who adopt a weak cosmopolitan approach
might endorse basic or minimal rights to healthcare, by arguing that a
basic standard of public health care should be available worldwide, yet
once such a basic standard of healthcare is in place, it is ethically permissible
that there be additional, costly and sophisticated, treatments for those
who can afford them.
A related global ethical issue is what has been called ‘the 90-10
disequilibrium’, which refers to the fact that that only 10% of total
health-related R&D is allocated to 90% of the
global disease  burden [19]. Put differently,
90 % of the  global disease  burden is made  up
of diseases that affect the global poor, such as
malaria, but only 10 % of the total money
spent on pharmaceutical R&D is allocated for
fighting these  diseases. This problem is further
exacerbated by the patent system ever since
the adoption of TRIPS (the Agreement on
Trade-Related Aspects of Intellectual Property
Rights) by the WTO in 1994. One of the main adverse implications of
this agreement has been the fact that it made the production of generic
drugs difficult (in developing countries such as Brazil and India), while it
made the sale of such drugs prohibited in underdeveloped countries that
lack the  necessary infrastructure  to  produce  such generic drugs.
10. Scientific integrity and responsibility
Research misconduct, in which principles of scientific integrity are  not
adhered to, is a significant problem in science today [20]. Although there
can be  a number of causes of scientific misconduct, the  issue  is further
exacerbated by the globalisation of scientific research. Firstly, with the
globalisation of research, scientists and researchers are increasingly coming
under the  pressure  to  publish and have  significant results faster due  to
increase in scientific competition, in particular within the knowledge
economies. Secondly, the globalisation of research makes it more difficult
to identify good research, given the divergent standards for scientific
integrity in different parts of the world. Thirdly, with the globalisation of
research there has been a growing need to publish in certain – globally
widespread – languages such as English, as a result of which, those
researchers lacking the required linguistic skills are increasingly feeling
the  pressure  to  plagiarise  research by those  who possess better linguistic
skills.
90 % of the global disease
burden is made up of
diseases that affect the
global poor, such as malaria,
but only 10 % of the total
money spent on pharma-
ceutical R&D is allocated
for fighting these
diseases.
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11. Issues of brain-drain
The globalisation of research and innovation, in particular the
globalisation of R&D, also contributes to the migrations of skilled scientists
and workers from developing countries to the developed countries.
Although not all instances of such migration of skilled people are necessarily
be negative, it can contribute to what has been described as “brain-
drain” [21]. Hence, the problem of brain-drain is a global problem that
can require both global and local solutions [22].
Ethical issues at the manufacturing and production stage
Besides the ethical issues arising in the R&D stage of innovation,
there  are  as well ethical issues in the  production and manufacture  phase
of innovation, which include issues concerning the adoption and
maintenance  of ethical standards in outsourcing, or off-shoring, of
production processes with regard to: (1) local workers and community
(e.g., outsourcing of production to  countries with lower wages or lower
standards for health and safety and protection of human rights); (2) local
environment (e.g., outsourcing of production processes, CO2 emissions
and waste disposal to countries with lower environmental standards).
1. Social implications
One  of the  main reasons for such outsourcing or off-shoring of production
and manufacture  processes to  developing countries is frequently said to
be reducing costs and freeing up assets in the short term [23]. Besides
short-term cost savings, there can be other reasons pertaining to efficiency,
such as making it possible for companies to focus their efforts on ‘core’
activities [24]. Nevertheless, as in the R&D stage of innovation activities,
outsourcing of production processes to  developing countries can be
motivated by the  availability of cheaper labour
and talent, cheaper infrastructure  and raw
materials, as well as lower standards in the
protection of employee health, occupational
and environmental safety, etc.
Although developing countries and regions
into which production processes are
outsourced in this way might come  to  enjoy
increased levels employment and GDP, the
globalisation of production processes can also give rise to exploitative
power relations, where  outsourcing companies gain benefits from softer or
non-existent legislation on matters of human rights and environmental
protection [25]. Outsou rcing of production to  countries with non-
The globalisation of research
and innovation, in particular
the globalisation of R&D,
also contributes to the
migrations of skilled
scientists and workers from
developing countries to the
developed countries.
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democratic, authoritarian or corrupt governments that place economic
gains above  social concerns can result in child labour, forced labour,
trampling of employee rights, abuse of employees, disregard of occupational
health and safety standards, etc. Moreover, it must be noted that global
outsourcing of production processes frequently has adverse  socio-economic
effects on wage and employment levels within developed countries as
well. Thus, for example, due to international economic competition, there
can be a “downward pressure on domestic salaries” [26].
2. Environmental implications
The environment is undoubtedly one of the prominent areas in
which some of the negative effects of the globalisation of technological
innovation are increasingly being felt [27]. There has thus been a
proliferation of issues, such as global warming and climate change,
environmental degradation (including water, soil and air pollution) resulting
from the  depletion of natural and non-renewable  resources, global
problems pertaining to waste disposal.
The  burdens of environmental side-effects of technological globalisation
are likely to be distributed disproportionately to the poor countries of
the world. The already vulnerable regions of the world are less capable
to mitigate such environmental effects. Thus, for example, rises in sea-
level will have a huge impact on low-lying and low-income states, such as
Bangladesh, and/or on small island states, such as Maldives. Although
this is in part to geographical location of these countries, there are as
well factors pertaining to the increasing global technological divide. Most
of these countries cannot afford the technological adaptations that richer
countries can possess: rises in temperature  are  better dealt with by countries
possessing drought management infrastructure; hurricanes and tsunamis
are more easily dealt with by those living in appropriate housing rather
than those inhabiting shanty towns; most environmental catastrophes are
more easily dealt with by richer countries that can provide immediate aid
to catastrophe affected regions.
All three stages of innovation activities pro-
duce waste. This is particularly true of the
production and manufacture  stage  of innova-
tion. Interestingly, in the age of digital infor-
mation technologies, some of the hazardous
waste comes from the so-called ‘clean technol-
ogies’, such as computers, high-tech and elec-
tronic equipment [28]. Thus, for example, the
processes of production of microchips entail the
The environment is
undoubtedly one of the
prominent areas in which
some of the negative
effects of the globali-
sation of technological
innovation are increa-
singly being felt.
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utilization of a variety of highly hazardous and toxic chemicals, such as
arsine, acetone, ethylene glycol and xylene [29]. Richer or developed
countries sometimes engage in global traffic in hazardous and toxic waste
that involves the  shipment of waste  from the
more developed countries to less developed
countries with lax environmental laws and reg-
ulations [30]. As a consequence of such out-
sourcing of waste  disposal, certain places of
the  globe  turn into  waste  dumping grounds,
such as the city of Guiyu in the Guangdong
region of China, which is the largest e-waste
recycling place in the world.
Ethical issues at the marketing and sales stage
Finally, at the marketing and sales stage of innovation activities, the
most notable of the ethical there are ethical issues pertaining to accessibility
or affordability of products and processes in different countries, as well as
responsibility and liability for health, environmental and other harms that
might result from the marketed and sold products.
1. Issues of affordability
One of the ethical issues that arises in the marketing and sales stage
of innovation activities is the issue of accessibility and affordability of
products and innovations in those developing countries where international
companies and multinational corporations come to monopolise the sales
of certain goods that serve basic needs (e.g., pharmaceuticals, foods, etc.)
and sell these goods at prices unaffordable in those developing countries.
2. Issues of liability
The fact that certain developing countries have limited regulation and
enforcement of product liability gives rise to the issue of (global)
responsibility and liability for the products marketed and sold in such
countries [31].
Concluding remarks
As can be seen from the above review of some of the most prominent
ethical issues stemming from the globalisation of research and innovation,
most of the ethical issues have to do with the fact that research and
innovation activities and practices in different countries and regions of the
world are subject to rather divergent, or altogether lacking, regulatory and
governing standards and practices. Under such circumstances, the
globalisation of research and innovation – whether in its R&D, production
Interestingly, in the age of
digital information technolo-
gies, some of the hazardous
waste comes from the so-
called ‘clean technologies’,
such as computers, high-
tech and electronic
equipment
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and manufacture  or marketing and sales stages, can easily lead to what has
been described as the problem of ‘double standards’ and/or ‘ethics
dumping’. In this context, any attempt to harmonise and bridge the ethical
gaps must be thoroughly thought through, given that such attempts might
involve a cross border diffusion of ethical and regulatory standards which
can potentially lead to a global imposition of values and interpretation, and
thus become instances of moral or ideological imperialism or neo-colonialism.
Further it should be  borne  in mind that when considering the  R&D
phase of science and technology, the present article has mainly focused
on moral and ethical issues surrounding the  participation of human subjects
in clinical and pharmaceutical trials and experimentation. However, this
somewhat biased focus on the role of human subjects in medical and
pharmaceutical research is not without defence, insofar as these areas of
research and innovation are widely considered to be among the most
morally charged, given their frequent involvement of vulnerable human
subjects, as well as the impact these areas can have on the wellbeing of
entire groups and communities.
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